EPISODE · Mar 20, 2026 · 13 MIN
Psychedelics at a Turning Point: The Trials That Could Change Mental Health Treatment
from WTR Healthcare Happenings · host Joe Brunetto
Robert Sassoon, WTR Senior Healthcare Analyst, joins Shawn Severson, CEO of WTR, to break down the latest clinical readouts in advanced psychedelics — including Compass Pathways’ Phase III progress in treatment-resistant depression, new anxiety data from Helus, and the upcoming milestones that could shape the future of mental health treatment. From durability and dosing models to regulatory momentum and investor implications, this episode explores why 2026 may be a pivotal year for the field.
What this episode covers
Robert Sassoon, WTR Senior Healthcare Analyst, joins Shawn Severson, CEO of WTR, to break down the latest clinical readouts in advanced psychedelics — including Compass Pathways’ Phase III progress in treatment-resistant depression, new anxiety data from Helus, and the upcoming milestones that could shape the future of mental health treatment. From durability and dosing models to regulatory momentum and investor implications, this episode explores why 2026 may be a pivotal year for the field.
NOW PLAYING
Psychedelics at a Turning Point: The Trials That Could Change Mental Health Treatment
No transcript for this episode yet
Similar Episodes
No similar episodes found.